SUCRALFATE-1 - TAB 1G 1 G
SUCRALFATE : 1 G · DIN 02130939 · PRO DOC LIMITEE
Health Canada status: CANCELLED POST MARKET
What is SUCRALFATE-1 - TAB 1G?
SUCRALFATE-1 - TAB 1G 1 G contains SUCRALFATE : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02130939, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 18-Jul-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02130939 |
|---|---|
| Brand name | SUCRALFATE-1 - TAB 1G |
| Generic / active ingredient | SUCRALFATE : 1 G |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 1 G |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A02BX02 SUCRALFATE |
| AHFS class | 28:08.04.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 18-Jul-2016 |
| Original market date | 1995-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A02BX02 SUCRALFATE. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SUCRALFATE - TAB 1G | 1 G | TABLET | APOTEX INC | MARKETED | DIN 02125250 |
| SULCRATE | 1 G | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02100622 |
| SULCRATE SUSPENSION PLUS | 1 G / 5 ML | SUSPENSION | ABBVIE CORPORATION | MARKETED | DIN 02103567 |
| TEVA-SUCRALFATE | 1 G | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02045702 |
| DOM-SUCRALFATE | 1000 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02239912 |
| NU-SUCRALFATE - TAB 1GM | 1 G | TABLET | NU-PHARM INC | CANCELLED POST MARKET | DIN 02134829 |
| PMS-SUCRALFATE | 1 G | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02238209 |
| SULCRATE SUS 100MG/ML | 100 MG | SUSPENSION | LABS NORDIC LABORATORIES INC. - SUBSIDARY OF M.M.D.C. | CANCELLED POST MARKET | DIN 00836370 |
Who else supplies SUCRALFATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUCRALFATE appears in 14 registered pack listings across 4 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.